News Release Details

Talaris Therapeutics Provides First FREEDOM-1 Phase 3 Clinical Update and Presents Additional Phase 2 Data and Analyses at American Society of Nephrology Meeting

November 04, 2021
  • First two Phase 3 patients treated with FCR001 more than 12 months prior to the data cutoff date both successfully weaned off all chronic immunosuppression (IS) without evidence of rejection and with stable kidney function
  • All Phase 3 patients who received FCR001 at least three months prior to the data cutoff date achieved and maintained >50% T-cell chimerism, which in Phase 2 correlated strongly with long-term, immunosuppression-free tolerance to the donated kidney
  • Overall safety profile of Phase 3 patients dosed to date with FCR001 is consistent with that observed in the Phase 2 study
  • In long-term follow up of Phase 2 patients, all 26 patients originally weaned off IS have continued to remain off IS without rejecting their donated kidney
  • Findings from urinary mRNA profiling of a subset of Phase 2 patients off all chronic IS lend additional support to hypothesis that these patients have been tolerized to their donated kidney

BOSTON and LOUISVILLE, Ky., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today provided the first clinical update on its Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients, and also separately presented a clinical update and additional data from ongoing follow-up of its fully-enrolled Phase 2 study in LDKT recipients at the 2021 American Society of Nephrology (ASN) meeting.

In the Phase 3 FREEDOM-1 study (NCT# 03995901), the first two study patients whose LDKT occurred more than 12 months prior to the data cutoff date were both successfully weaned off all chronic immunosuppression (IS) drugs without evidence of rejection and with stable kidney function and continue to remain off all IS through the data cut-off date. Furthermore, all patients treated at least three months prior to the cutoff date with the Company’s Facilitated Allo-HSCT Therapy, FCR001, achieved T-cell chimerism levels >50% at each of the 3-, 6-, and 12-month timepoints post-transplant. In the Company’s Phase 2 study, establishment and maintenance of >50% donor peripheral T-cell chimerism in an LDKT recipient at 3, 6 and 12 months after administration of FCR001 all correlated strongly with the patient’s ability to durably discontinue chronic IS approximately one year after transplant, without subsequent graft rejection.

The Company also presented “Preserved kidney allograft function and unique urinary biomarker profiles in living-donor kidney transplant patients tolerized with an investigational allo-HSCT cell therapy” (PO2040) at the 2021 ASN meeting. This poster reported that, in continued long-term follow-up of patients treated in the Company’s Phase 2 study of FCR001 (median >6 years), kidney allograft function was preserved in all patients who had been successfully weaned off chronic IS and such patients have continued to remain off chronic IS for the duration of their follow up. Further, Talaris reported that it has identified potential signals of immune quiescence in the kidneys of some of its Phase 2 LDKT patients who were tolerized to their donated kidney, as compared to standard of care kidney transplant patients.

“We are very encouraged by these initial data from the first kidney transplant recipients dosed with FCR001 in our FREEDOM-1 study,” said Scott Requadt, Chief Executive Officer. “With 14 top-tier clinical sites now actively recruiting across the United States and COVID-related delays easing, we look forward to accelerating our enrollment and providing additional updates as more patients are dosed.”

“Today, organ transplant recipients must take lifelong immunosuppression, which comes with significant morbidities, risks and quality of life challenges. A treatment alternative for these patients is greatly needed,” noted Joseph Leventhal, M.D., Ph.D., Fowler McCormick Professor of Surgery at Northwestern University Feinberg School of Medicine, and principal investigator for the FREEDOM-1 trial. “I am very pleased to see that the first two patients in the study, who are both more than twelve months from their transplant, have been able to discontinue all chronic immunosuppression without rejecting their donated kidney.”

Initial Phase 3 FREEDOM-1 Highlights

The Company provided an update on the first 5 patients dosed with its investigational Facilitated Allo-HSCT Therapy FCR001 in its FREEDOM-1 study. FREEDOM-1 is a randomized, controlled, open-label Phase 3 registrational study of FCR001 in 120 adult LDKT recipients in the United States. The primary endpoint of FREEDOM-1 is the proportion of kidney transplant recipients treated with FCR001 who are free from chronic IS, without biopsy-proven acute rejection (BPAR), at month 24 post-transplant.

  • Enrollment, demographics and degree of HLA mismatching.   A total of 11 LDKT donor-recipient pairs have been enrolled to date in the FREEDOM-1 study at a total of 5 clinical sites. Of these, 7 were randomized to receive FCR001 and 4 were randomized to the control arm. Currently, 5 of those randomized to FCR001 have received their kidney transplant and have been dosed with FCR001. All donors and recipients were between 18 – 65 years of age and met the eligibility criteria for inclusion in the FREEDOM-1 study. Figure 1 shows the distribution of all FCR001 recipients dosed to date, by the number of HLA mismatches between the donor and the recipient.
  • FCR001 patients achieving >50% T-cell chimerism by timepoint and discontinuation of chronic immunosuppression (IS) after 12 months. As shown in Figure 2, a total of five patients have been dosed through the data cutoff date, two of whom are more than 12 months post-transplant. Both demonstrated >50% T-cell chimerism at each of the 3-, 6- and 12-month timepoints and have been discontinued from chronic IS. One patient is more than six months post-transplant and has demonstrated >50% T-cell chimerism at the 3- and 6-month timepoints. The remaining two patients have not yet met the 3-month timepoint.

  • In the context of transplantation, chimerism refers to a state wherein both the donor’s and the recipient’s hematopoietic stem cells (HSCs) coexist in the recipient’s bone marrow. Talaris believes chimerism to be an important potential study biomarker, predictive of inducing a state of allogeneic tolerance in the recipient, whereby the recipient tolerates the donated organ without the need for chronic IS. Achieving durable donor T-cell chimerism in the LDKT recipient is one of the goals of the Company’s Facilitated Allo-HSCT Therapy. In the Company’s Phase 2 study, establishment and maintenance of >50% donor peripheral T-cell chimerism in an LDKT recipient at 3, 6 and 12 months after administration of FCR001 all correlated strongly with the patient’s ability to durably discontinue chronic IS approximately one year after transplant, without subsequent graft rejection.
  • Phase 3 safety profile in FCR001-dosed patients. The adverse events (AEs) and serious adverse events (SAEs) observed to date in the FCR001-dosed patients are consistent with kidney and stem cell transplantation involving non-myeloablative conditioning and with what was observed in the Phase 2 study. No events occurred to cause the Data Safety Monitoring Board (DSMB) to stop or modify the study protocol, nor was any stopping rule triggered.

    To date, no FCR001-dosed patients in the Phase 3 study have experienced BPAR. Moreover, to date, none of the 5 patients dosed with FCR001 in the Phase 3 study have developed donor-specific antibodies (DSA), the presence of which post-transplant predicts an increased risk for antibody-mediated rejection of the donated organ.

Phase 2 Long-Term Follow-Up Study Updates

  • Consistent durability off IS and safety profile. In a poster presented at the 2021 ASN meeting, Talaris provided an update on the continued long-term follow-up of patients in its Phase 2 LDKT study. Talaris previously reported that 26 of 37 (70%) patients in its Phase 2 study achieved stable T-cell chimerism and were weaned off all chronic IS by approximately 12 months after their transplant. To date, 26 of 26 patients (100%) weaned off IS have continued to remain off chronic IS for the duration of their follow-up without rejecting their donated kidney. Talaris has followed these patients for a median >6 years and the longest >12 years. Six of these transplant recipients have now exceeded 10 years off all chronic IS without BPAR.   Through June 11, 2021, the date of the most recent DSMB meeting for the Phase 2 study, there have been no additional AEs or SAEs reported since the prior Phase 2 data cut-off date that were determined to be related to FCR001.
    • The ability to discontinue chronic immunosuppression was observed across all levels of donor and recipient HLA matching, with 19 out of 26 recipients (73%) who were able to durably discontinue their chronic IS having an HLA match of three or less to their donor. In the Phase 2 study, Talaris did not observe any correlation between the degree of HLA mismatch and the safety or efficacy measures in the study.
    • As of October 1, 2021, Talaris has accumulated over 250 patient-years of exposure to FCR001 in LDKT, and the safety profile observed in the Phase 2 patients remains generally consistent with that expected of a patient who receives both a standard living donor kidney transplant and an allo-HSCT with nonmyeloablative conditioning.
    • Most adverse events in the Phase 2 study occurred during the first 12 months post-transplant when the patients were on conventional immunosuppression.

New Poster Describes Potential Additional Signal of Immune Quiescence

  • Potential urinary biomarker of immune quiescence. In a poster presented at the 2021 ASN meeting, Talaris reported findings of urinary mRNA profiling that it performed in a subgroup of Phase 2 LDKT patients who were tolerized to their donated kidney, as well as in a biopsy-matched cohort of standard of care LDKT recipients on chronic IS. In this analysis, Talaris identified potential signals of greater immune quiescence in the kidneys of tolerized patients, as compared to the cohort of biopsy-matched standard of care kidney transplant patients. These findings may provide further support that these patients have been tolerized to their donated kidney.

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage biopharmaceutical company developing investigational, one-time, allogeneic cell therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders. Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com, and follow Talaris on TwitterLinkedIn and Facebook.

About the FREEDOM-1 Clinical Study
FREEDOM-1 is a Phase 3 clinical research study of an investigational cell therapy called FCR001. The purpose of the study is to learn more about whether FCR001 can prevent the rejection of living donor kidney transplants without the need for lifelong anti-rejection drugs. The study will compare the efficacy and safety of FCR001 treatment to standard anti-rejection treatment and is now enrolling adults who plan to undergo a living donor kidney transplant. More information can be found at https://freedom1study.com or at https://www.clinicaltrials.gov/ct2/show/NCT03995901.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Talaris Therapeutics, Inc.’s (“Talaris,” the “Company,” “we,” or “our”) strategy, business plans and focus; the progress and timing of the preclinical and clinical development of Talaris’ programs, including FCR001 and FCR002; expectations regarding the dosing of additional patients in Talaris’ FREEDOM-1 study; and expectations regarding the identification of a potential signature of tolerance. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with the impact of COVID-19 where the Company has operations or does business, as well as on the timing and anticipated timing and results of its clinical trials; the risk that the strategy and future operations of the Company, including the expected timing, enrollment, and results from the FREEDOM-1 study will not meet expectations; the risk that early data from the FREEDOM-1 study may not be predictive of or consistent with final results; the risk that the results of Talaris’ earlier clinical trials may not be predictive of future results in connection with future clinical trials; and the risk that the Company may not be able to successfully demonstrate the safety and efficacy of its drug candidates, including FCR001. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Talaris’ views only as of today and should not be relied upon as representing our views as of any subsequent date. Talaris explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com 
(339) 970-2843


Print Page
RSS Feeds
Email Alerts
Email Page